🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#TexasLung25-awesome time with the best community! 🩵 #lungcancer ➡️ Let’s also send huge thanks to: 🙏 IDEOlogy Health team for hard work in organizing behind the scenes! 🙏 colleagues covering at home 🙏 patients who inspire us every day TLC Conference Stephen V Liu, MD IASLC

Thoroughly enjoyed #TexasLung25. A complete overview of thoracic oncology landscape. Thank you Stephen V Liu, MD Dr. Tina Cascone for your thoughtful organization of the meeting. Eric K. Singhi, MD Mara Antonoff, MD, FACS Narjust Florez, MD, FASCO Sandip Patel MD FASCO Dr. Estela Rodriguez Christian Rolfo Mary Jo Foley

Retrospective report on temozolomide use for relapsed #SCLC Lung Cancer Journal. In 47 pts, temozolomide (250mg d1-5 q28d) had RR of 14.9%, DCR 23.4%, mPFS 1.7m, mOS 3.2m with G3+ TRAEs in 34% of pts. Fortunately, better options now emerging for SCLC. lungcancerjournal.info/article/S0169-…

Thank you to our incredible faculty for making #TexasLung25 a success! Your expertise, insightful discussions, and commitment to advancing lung cancer care were key to making this 2-day CE-accredited conference truly memorable. hubs.la/Q03hrM860

On #LungCancerConsidered, Narjust Florez, MD, FASCO & Corey Langer break down key data from #ELCC25, including MARIPOSA, ORCHARD & SOHO-01 trials—plus insights on managing treatment toxicity in lung cancer. 🎧 Listen now: bit.ly/LCC25ELCC #ELCC25

Thanks to Mike Posner for his keynote presentation at #TexasLung25 - for reminding us of the power of breath and for giving us all some much needed motivation and perspective. ❤️

Pragmatic, open label ACHILLES/TORG1834 trial of 1L afatinib vs chemotherapy in uncommon #EGFR NSCLC Journal of Clinical Oncology. 109 pts randomized 2:1 to afatinib. Outcomes favored afatinib: PFS 10.6 vs 5.7m (HR 0.42) with RR 56-73%, varying by specific mutation. ascopubs.org/doi/10.1200/JC…

Report on oncogenic #MET fusions Cancer Discovery - in analysis of >46,000 solid tumors, MET rearrangements seen in ~0.04%. Phase II study of the type I MET TKI vebreltinib here showed RR 50% and DCR 79%, with activity seen in NSCLC, cholangiocarcinoma, others. aacrjournals.org/cancerdiscover…

Here is the thing friends… She went for it! I am running for the IASLC Board of Directors because I believe in the organization & all it can do for our patients and community And we together can make a DIFFERENCE Undesignated Group # 4 - Vote 🗳️ #LCSM

Perspective on unintended consequences of patient portal access JAMA Oncology. Came as a result of the 21st Century Cures Act in 2021 to empower patients and increase transparency. But providing information without context can lead to confusion & anxiety... jamanetwork.com/journals/jamao…

📺 Watch Drs. Stephen V Liu, MD and Benjamin Weinberg, MD, FACP of Georgetown Lombardi discuss the prevalence of NRG1 gene fusions in #pancreatic ductal adenocarcinoma, along with strategies they recommend for effectively identifying these fusions in clinical practice: buff.ly/WSdZtcx

All IASLC members - be sure to vote in the Board of Directors election now! Great to see such passionate and amazing candidates this year including Hidehito HORINOUCHI for Undesignated Seat #2, Navneet Singh for Countries Not Previously Represented, and my podcast co-host Narjust Florez, MD, FASCO

🚨Delighted to share our latest publication in ASCO journal JCO Precision Oncology courtesy of our brilliant Sarah Cannon Docs colleagues at our London led by Dr. Elisa Fontana. Thrilled to collaborate with the amazing Charles Swanton 👉🏼 "Safety and Activity of Fibroblast Growth Factor

🔥 JTO & JTO CRR IASLC 🆙 ✅SQUAT trial (WJOG 12119L): Neoadju Concurrent Chemo-immuno-radiation Tx ➡️ Surgery ➡️ Adju Immunotherapy for Resectable Stage III N2 NSCLC 🎯MPR/pCR: 63/23%, 2y PFS/OS: 43/76% 👥 Dr. Akira Hamada Tetsuya Mitsudomi #LCSM OncoAlert jto.org/article/S1556-…

Early safety results from Phase III NARLAL2 trial: FDG to escalate definitive radiation dose from standard 66Gy to 88Gy in locally advanced NSCLC Journal of Clinical Oncology. No difference in early toxicity: G2/3 esophagitis 28%/16% vs 26%/20% in standard & escalated arms. ascopubs.org/doi/10.1200/JC…